Active substance
Dienogest
- SFDA 2
- Health Canada 5
- NHS prices 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Noveen | 2 mg | Film-coated tablet · Oral use | 28 Blister | SAR 160.35 | Generic · Prescription | KEURO LIFE LIMITED COMPANY | Valid |
| VISANNE 2MG TABLETS | 2 mg | Tablet · Oral use | 28 Blister | SAR 209.20 | NCE · Prescription | BAYER PHARMA AG | Valid |
Indications — CHI Daman Drug Formulary
ENDOMETRIOSIS; MENSTRUAL DISORDERS
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ASPEN-DIENOGEST | 02493055 | 2 MG | TABLET · ORAL | ASPEN PHARMACARE CANADA INC. |
| JAMP DIENOGEST | 02498189 | 2 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| M-DIENOGEST | 02543613 | 2 MG | TABLET · ORAL | MANTRA PHARMA INC |
| MAR-DIENOGEST | 02551683 | 2 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| VISANNE | 02374900 | 2 MG | TABLET · ORAL | BAYER INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Dienogest 2mg tablets | £19.51 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 26 Jun 2024 NATAZIA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.